The same week Annexon Biosciences announced it had raised $100 million in private financing to advance its research of antibody drugs to treat neurodegeneration, the company filed paperwork with regulators indicating... Read more »
MEI Pharma and its Swiss partner Helsinn are ending a Phase 3 study of an investigational cancer drug for patients with acute myeloid leukemia (AML) after an interim analysis indicated it... Read more »
Annexon Biosciences, a biotech founded in late 2014 by former Elan Pharmaceuticals executives, has added $100 million to its coffers to move its two clinical-stage programs along and to continue advancing... Read more »
Ten months ago Randy Schatzman was appointed CEO of cancer drug developer Bolt Biotherapeutics, and tasked with getting its first drug candidate into the clinic, building out its C-suite, and... Read more »
The blood-brain barrier protects the functioning of that essential organ, but it’s also a hurdle to delivering neurological drugs.
Italy’s Chiesi Group has agreed to pay Guilford, CT-based Bioasis Technologies $3... Read more »
A growing population of people with software experience plus an interest in life sciences is boosting drug development in the San Francisco Bay Area, according to panelists at an Xcelerating event.... Read more »
A new version of a combination drug marketed by Roche for early-stage and metastatic breast cancer with a specific genetic signature received FDA approval Monday for a formulation that can be... Read more »
Heron Therapeutics revealed Monday that its investigational non-opioid drug for treating postoperative pain has again been rejected by the FDA.
The San Diego company’s HTX-011 is an extended-release solution of bupivacaine,... Read more »
DBV Technologies still expects to receive an FDA decision in early August for its peanut allergy patch. But on Friday the company, which is headquartered in the southern outskirts of Paris,... Read more »
Creating cell therapies for cancer is a complex process. The business case for them has proven tricky, too.
Biotech veterans Tom Farrell and Peter Flynn have teamed up to start a... Read more »
Uncertainty related to the continued spread of the pandemic continued to consume most of the oxygen in the room this week, but life sciences news outside of that arena continued apace.... Read more »
Sophisticated computational tools have guided Relay Therapeutics in its efforts to develop new drugs based on analysis of the movement and shape of disease-causing proteins.
Now the Cambridge, MA, biotech is... Read more »
Reneo Pharmaceuticals has encouraging results from an early trial of a compound it is advancing for rare diseases characterized by impaired mitochondria—our cells’ energy generators—and the company says it is now... Read more »
Effective checkpoint inhibitors facilitate immune cells’ ability to recognize and target tumors. But for some patients this approach to treating cancer doesn’t work. Pionyr Immunotherapeutics aims to help those people by... Read more »
Tiny, naturally occurring particles called exosomes shuffle molecular payloads between cells, facilitating intercellular communication. Codiak Biosciences’ focus is using those nanoparticles to more safely deliver a range of medicines to specific... Read more »
The science underpinning the latest investigational cell and gene therapies is complex enough. But the rapid advance of technologies that support development of these kinds of drugs presents logistical considerations, too.... Read more »
Ten years ago Mark Smith was at MIT doing basic research into the microbiome. Now, as CEO of Finch Therapeutics Group, Smith has hard data to back up his company’s thesis... Read more »
Typically a new biotech assembles a group of investors that collectively puts in the money a fledgling company requires to develop or acquire potential therapies.
Engrail Therapeutics, which emerged from stealth... Read more »
Lassen Therapeutics, a biotech that is developing antibodies as potential treatments for fibrosis, rare diseases, and cancer, debuted Wednesday with $31 million in Series A financing.
The San Diego-based company says... Read more »
C4 Therapeutics, a biotech developing small molecules designed to take advantage of a cellular mechanism as a way to treat disease, has raised $170 million in venture equity and debt to... Read more »